http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1149670-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate | 1966-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1969-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1149670-A |
| titleOfInvention | Improvements in or relating to novel nucleotides and the manufacture thereof |
| abstract | 1,149,670. Dinucleotides. UPJOHN CO. 29 April, 1966 [1 June, 1965], No. 19037/66. Heading C2C. The invention comprises dinucleotides of formulµ where X 1 is H, α-OH or #-OH and X 1 <SP>1</SP> is H, α-O-acyl or #-O-acyl with the proviso that only one ring can be ribofuranose; the combination X 2 and X 3 is H, α-OH; H; #-OH; α-OH; #-OH; #-OH, α-OH; or #-OH; #-OH and the combination X 2 and X 3 1 x is H, α-O-acyl; H - # - O - acyl; α - OH; # - O - acyl; #-OH, α-O-acyl and #-OH, #-O-acyl; Y 1 and Y 2 are cytosin - 1 - yl, uracil - 1 - yl, thymin - 1 - yl, adenin - 9 - yl, guanin - 9 - yl, 6 - mercaptopurin - 9 - yl, uracil - 3 - yl, 5 - fluorouracil - 1- yl, 5 - chlorouracil - 1 - yl, 5 - bromouracil - 1- yl, 5 - iodouracil - 1 - yl, 5 - trifluoromethyluracil - 1 - yl, hypoxanthin - 9 - yl, xanthin - 9- yl, 5 - methylcytosin - 1 - yl or 3 - methylcytosin-1-yl and Y 1 <SP>1</SP> and Y 2 <SP>1</SP> are the same groups in which any amino or imino groups are acylated; Ac<SP>1</SP> and the above mentioned acyl groups are acyl groups of C 2-12 hydrocarbon monocarboxylic acids or anisoyl; T is triphenylmethyl, (p - methoxyphenyl) diphenylmethyl or bis (p-methoxyphenyl) phenylmethyl; and the vertical wavy line indicates that the attached substituents may be below (α-) or above (#-) the plane of the ring, and the pharmaceutically acceptable salts of (XI) and (XII). They may be prepared by reacting a nucleoside of Formula VII with a nucleotide of Formula VI in which X, X<SP>1</SP> and Y<SP>1</SP> are as for X 1 , X 1 1 and Y 1 <SP>1</SP> above respectively, in the presence of a dialkylcarbodiimide to give (IX) and (X) which may be hydrolysed with base followed by acid to give (XI) and (XII). (IX) and (X) or (XI) and (XII) may be separated by ion exchange chromatography or solvent extraction in a Craig apparatus. N<SP>4</SP> - Benzoyl - 1 - # - D - arabinofuranosylcytosine is prepared by alkaline hydrolysis of N<SP>4</SP> - benzoyl - 1 - (21,31 - di - O - benzoyl - # - D- arabinofuranosyl)cytosine. Pharmaceutical compositions comprising compounds (XII) and their salts have antiviral activity. |
| priorityDate | 1965-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.